3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
34
Paraganglioma
6
Meningioma
6
Gastro-enteropancreatic neuroendocrine tumor
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Neuroblastoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Interventions
Ifosfamide
30
Methotrexate
27
Doxorubicin
25
Cyclophosphamide
24
Cisplatin
22
Filgrastim
18
Etoposide
17
Gemcitabine
16
Leucovorin
14
Magnetic Resonance Spectroscopy
11
Temozolomide
10
cabozantinib
9
apatinib
9
Specimen Handling
9
Carboplatin
9
fludarabine
8
X-Rays
8
Nivolumab
8
Neoadjuvant Therapy
8
Irinotecan
8
Granulocyte Colony-Stimulating Factor
8
Docetaxel
8
Zoledronic Acid
7
Vincristine
7
Sirolimus
7
Radiotherapy
7
Phantoms, Imaging
7
Biopsy
7
Topotecan
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Osteosarcoma
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled